Immuneering Corporation (IMRX)

Immuneering Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	-	-	-	0.32	2.08
Revenue Growth (YoY)	-	-	-	-	-84.76%	-10.02%
Cost of Revenue	-	-	-	-	0.16	1.15
Gross Profit	-	-	-	-	0.16	0.93
Selling, General & Admin	17.98	17.3	16.08	16.76	15.61	8.27
Depreciation & Amortization Expenses	0.03	0.03	0.03	0.03	0.03	-
Research & Development	41.22	42.05	47.96	41.62	36.27	26.54
Total Operating Expenses	59.23	59.38	64.07	58.41	51.9	34.81
Operating Income	-59.23	-59.38	-64.07	-58.41	-51.74	-33.89
Interest Income	3.96	3.04	2.59	3.61	1.01	0.17
Other Non-Operating Income (Expense)	0.83	0.31	0.44	1.33	0.22	-0.13
Total Non-Operating Income (Expense)	4.79	3.35	3.03	4.94	1.23	0.04
Pretax Income	-54.44	-56.02	-61.04	-53.47	-50.51	-33.84
Provision for Income Taxes	-	-	-	-	-	-0.31
Net Income	-54.44	-56.02	-61.04	-53.47	-50.51	-33.54
Net Income to Common	-54.44	-56.02	-61.04	-53.47	-50.51	-33.54
Shares Outstanding (Basic)	51	44	30	28	26	14
Shares Outstanding (Diluted)	51	44	30	28	26	14
Shares Change (YoY)	62.53%	46.80%	5.51%	7.69%	93.84%	175.00%
EPS (Basic)	-1.17	-1.27	-2.04	-1.88	-1.91	-2.46
EPS (Diluted)	-1.17	-1.27	-2.04	-1.88	-1.91	-2.46
Shares Outstanding	64.69	64.65	31.05	29.27	26.42	26.32
Free Cash Flow	-49.91	-45.49	-55.08	-49.31	-44.84	-30.91
Free Cash Flow Per Share	-0.97	-1.03	-1.84	-1.74	-1.70	-2.27
Gross Margin	-	-	-	-	50.11%	44.56%
Operating Margin	-	-	-	-	-16325.80%	-1629.17%
Profit Margin	-	-	-	-	-15937.30%	-1612.33%
FCF Margin	-	-	-	-	-14148.40%	-1486.17%
EBITDA	-58.88	-59.02	-63.69	-58.06	-51.47	-33.84
EBITDA Margin	-	-	-	-	-16238.30%	-1626.98%
EBIT	-59.23	-59.38	-64.07	-58.41	-51.74	-33.89
EBIT Margin	-	-	-	-	-16325.80%	-1629.17%
Effective Tax Rate	-	0.00%	0.00%	0.00%	0.00%	0.91%

Updated May 15, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q